Cargando…

Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016

OBJECTIVE: The aim of this study was to investigate the in vitro antimicrobial susceptibilities of clinically important Gram-negative bacteria from seven intensive care units in Taiwan in 2016. MATERIALS AND METHODS: In total, 300 non-duplicate isolates of Escherichia coli (n=100), Klebsiella pneumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Chun-Hsing, Lee, Na-Yao, Tang, Hung-Jen, Lee, Susan Shin-Jung, Lin, Chin-Fu, Lu, Po-Liang, Wu, Jiunn-Jong, Ko, Wen-Chien, Lee, Wen-Sen, Hsueh, Po-Ren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404672/
https://www.ncbi.nlm.nih.gov/pubmed/30881060
http://dx.doi.org/10.2147/IDR.S193638
_version_ 1783400938318331904
author Liao, Chun-Hsing
Lee, Na-Yao
Tang, Hung-Jen
Lee, Susan Shin-Jung
Lin, Chin-Fu
Lu, Po-Liang
Wu, Jiunn-Jong
Ko, Wen-Chien
Lee, Wen-Sen
Hsueh, Po-Ren
author_facet Liao, Chun-Hsing
Lee, Na-Yao
Tang, Hung-Jen
Lee, Susan Shin-Jung
Lin, Chin-Fu
Lu, Po-Liang
Wu, Jiunn-Jong
Ko, Wen-Chien
Lee, Wen-Sen
Hsueh, Po-Ren
author_sort Liao, Chun-Hsing
collection PubMed
description OBJECTIVE: The aim of this study was to investigate the in vitro antimicrobial susceptibilities of clinically important Gram-negative bacteria from seven intensive care units in Taiwan in 2016. MATERIALS AND METHODS: In total, 300 non-duplicate isolates of Escherichia coli (n=100), Klebsiella pneumoniae (n=100), and Pseudomonas aeruginosa (n=100) collected from 300 patients were studied. The minimum inhibitory concentrations (MICs) of these isolates to antimicrobial agents were determined using the broth microdilution method. Carbapenemase-encoding genes (bla(KPC), bla(NDM), bla(IMP), bla(VIM), and bla(OXA-48-like)) were studied for the isolates that were not susceptible to any carbapenems. Sequencing analysis of the mcr genes (mcr-1–5) was conducted for all isolates with colistin MICs ≥4 mg/L. RESULTS: Ertapenem non-susceptibility was detected in 3% (n=3) E. coli and 12% (n=12) K. pneumoniae isolates. The susceptibility rates of imipenem, ceftazidime–avibactam (CAZ–AVB), and ceftolozane–tazobactam (CLZ–TAZ) were 99%, 99%, and 88%, respectively, for E. coli, 91%, 100%, and 80%, respectively, for K. pneumoniae, and 66%, 91%, and 93%, respectively, for P. aeruginosa. Carbapenemase-encoding genes were not detected in E. coli, were detected in four (33.3%) K. pneumoniae isolates that were not susceptible to ertapenem (three harboring bla(KPC) and one harboring bla(OXA-48-like)), and were not detected in P. aeruginosa isolates that were not susceptible to imipenem. One K. pneumoniae isolate was resistant to colistin (MIC 4 mg/L) and negative for mcr genes. CONCLUSION: CAZ–AVB exhibited excellent activity against carbapenem-resistant Enterobacteriaceae, and CLZ–TAZ exhibited good activity against imipenem-resistant P. aeruginosa.
format Online
Article
Text
id pubmed-6404672
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-64046722019-03-16 Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016 Liao, Chun-Hsing Lee, Na-Yao Tang, Hung-Jen Lee, Susan Shin-Jung Lin, Chin-Fu Lu, Po-Liang Wu, Jiunn-Jong Ko, Wen-Chien Lee, Wen-Sen Hsueh, Po-Ren Infect Drug Resist Original Research OBJECTIVE: The aim of this study was to investigate the in vitro antimicrobial susceptibilities of clinically important Gram-negative bacteria from seven intensive care units in Taiwan in 2016. MATERIALS AND METHODS: In total, 300 non-duplicate isolates of Escherichia coli (n=100), Klebsiella pneumoniae (n=100), and Pseudomonas aeruginosa (n=100) collected from 300 patients were studied. The minimum inhibitory concentrations (MICs) of these isolates to antimicrobial agents were determined using the broth microdilution method. Carbapenemase-encoding genes (bla(KPC), bla(NDM), bla(IMP), bla(VIM), and bla(OXA-48-like)) were studied for the isolates that were not susceptible to any carbapenems. Sequencing analysis of the mcr genes (mcr-1–5) was conducted for all isolates with colistin MICs ≥4 mg/L. RESULTS: Ertapenem non-susceptibility was detected in 3% (n=3) E. coli and 12% (n=12) K. pneumoniae isolates. The susceptibility rates of imipenem, ceftazidime–avibactam (CAZ–AVB), and ceftolozane–tazobactam (CLZ–TAZ) were 99%, 99%, and 88%, respectively, for E. coli, 91%, 100%, and 80%, respectively, for K. pneumoniae, and 66%, 91%, and 93%, respectively, for P. aeruginosa. Carbapenemase-encoding genes were not detected in E. coli, were detected in four (33.3%) K. pneumoniae isolates that were not susceptible to ertapenem (three harboring bla(KPC) and one harboring bla(OXA-48-like)), and were not detected in P. aeruginosa isolates that were not susceptible to imipenem. One K. pneumoniae isolate was resistant to colistin (MIC 4 mg/L) and negative for mcr genes. CONCLUSION: CAZ–AVB exhibited excellent activity against carbapenem-resistant Enterobacteriaceae, and CLZ–TAZ exhibited good activity against imipenem-resistant P. aeruginosa. SAGE Publications 2019-03-04 /pmc/articles/PMC6404672/ /pubmed/30881060 http://dx.doi.org/10.2147/IDR.S193638 Text en © 2019 Liao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Liao, Chun-Hsing
Lee, Na-Yao
Tang, Hung-Jen
Lee, Susan Shin-Jung
Lin, Chin-Fu
Lu, Po-Liang
Wu, Jiunn-Jong
Ko, Wen-Chien
Lee, Wen-Sen
Hsueh, Po-Ren
Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016
title Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016
title_full Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016
title_fullStr Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016
title_full_unstemmed Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016
title_short Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016
title_sort antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against escherichia coli, klebsiella pneumoniae, and pseudomonas aeruginosa isolated from intensive care units in taiwan: results from the surveillance of multicenter antimicrobial resistance in taiwan in 2016
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404672/
https://www.ncbi.nlm.nih.gov/pubmed/30881060
http://dx.doi.org/10.2147/IDR.S193638
work_keys_str_mv AT liaochunhsing antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani
AT leenayao antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani
AT tanghungjen antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani
AT leesusanshinjung antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani
AT linchinfu antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani
AT lupoliang antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani
AT wujiunnjong antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani
AT kowenchien antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani
AT leewensen antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani
AT hsuehporen antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani